Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC)...
October 18 2017 - 4:10PM
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel immuno-oncology therapies, today
announced that it will present data on lead checkpoint inhibitor
CPI-444 from its ongoing Phase 1/1b study in an oral session at the
Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting,
which is taking place November 8-12 in National Harbor, Maryland.
Following are the details for the oral presentation.
Oral Presentation
Title: Clinical Activity of Adenosine A2a
Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor
Expression of Adenosine Pathway Genes and Tumor Immune
ModulationPresenter: Jason J. Luke, M.D., FACP,
Assistant Professor of Medicine, University of Chicago
MedicineSession: Clinical Trials: Novel
CombinationsPresentation Date and Time: November
11, 2017, 5:45 - 6:00 p.m. EST
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of small molecule
and antibody agents that target the immune system to treat patients
with cancer. These agents block or modify crucial immune
checkpoints and reprogram immune T-cells. Corvus’ lead product,
CPI-444, is a checkpoint inhibitor that is designed to disable a
tumor’s ability to subvert attack by the immune system by
inhibiting adenosine in the tumor microenvironment. CPI-444 is a
small molecule that is taken orally. CPI-444 is currently being
evaluated in a multicenter Phase 1/1b clinical trial in patients
with various solid tumors. This successive expansion cohort trial
is examining the activity of CPI-444 both as a single agent and in
combination with Genentech’s Tecentriq® (atezolizumab), an
anti-PD-L1 antibody. Corvus is conducting the trial with Genentech,
a member of the Roche Group, under a clinical trial collaboration
the two companies entered into in October 2015. For more
information, visit: www.corvuspharma.com.
Tecentriq® (atezolizumab) is a registered trademark of
Genentech.
Corvus Contact:Guillermo Elias, PhDDirector,
Business Development Corvus Pharmaceuticals, Inc.
+1-650-889-4377GElias@corvuspharma.com
Media Contact:Julie NormartPure
Communications+1-415-946-1087jnormart@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2023 to Apr 2024